RU2019117562A - Соединения и их фармацевтические композиции для лечения воспалительных заболеваний - Google Patents
Соединения и их фармацевтические композиции для лечения воспалительных заболеваний Download PDFInfo
- Publication number
- RU2019117562A RU2019117562A RU2019117562A RU2019117562A RU2019117562A RU 2019117562 A RU2019117562 A RU 2019117562A RU 2019117562 A RU2019117562 A RU 2019117562A RU 2019117562 A RU2019117562 A RU 2019117562A RU 2019117562 A RU2019117562 A RU 2019117562A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- subject
- sarcoidosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201618959 | 2016-11-10 | ||
| GB201618962 | 2016-11-10 | ||
| GB201618963 | 2016-11-10 | ||
| GB1618959.9 | 2016-11-10 | ||
| GB1618962.3 | 2016-11-10 | ||
| GB1618963.1 | 2016-11-10 | ||
| GB1618961.5 | 2016-11-10 | ||
| GB1618960.7 | 2016-11-10 | ||
| GB1618964.9 | 2016-11-10 | ||
| GB201618961 | 2016-11-10 | ||
| GB201618964 | 2016-11-10 | ||
| GB201618960 | 2016-11-10 | ||
| PCT/EP2017/078701 WO2018087202A1 (en) | 2016-11-10 | 2017-11-09 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019117562A true RU2019117562A (ru) | 2020-12-10 |
| RU2019117562A3 RU2019117562A3 (cg-RX-API-DMAC7.html) | 2021-02-09 |
Family
ID=60388032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019117562A RU2019117562A (ru) | 2016-11-10 | 2017-11-09 | Соединения и их фармацевтические композиции для лечения воспалительных заболеваний |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190314382A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3538103A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019534304A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017358703A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3043396A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019117562A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201821080A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018087202A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019132654A1 (en) * | 2017-12-27 | 2019-07-04 | Erasmus University Medical Center Rotterdam | Methods of treating sarcoidosis |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| WO2020009566A1 (en) * | 2018-07-04 | 2020-01-09 | Erasmus University Medical Center Rotterdam | Methods of treating sarcoidosis |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
| US11602536B2 (en) | 2019-06-10 | 2023-03-14 | Incyte Corporation | Topical treatment of vitiligo by a JAK inhibitor |
| JP7518900B2 (ja) * | 2019-10-16 | 2024-07-18 | インサイト・コーポレイション | 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用 |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| CN115282168B (zh) * | 2022-08-30 | 2024-05-31 | 马应龙大健康有限公司 | 一种缓解婴幼儿湿疹症状的舒缓润肤霜及其制备方法和应用 |
| CN119157881A (zh) * | 2024-09-25 | 2024-12-20 | Jje有限公司 | Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070111956A1 (en) | 2003-07-03 | 2007-05-17 | Japan Science And Technology Agency | Remedy for sarcoidosis and method of treating the same |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| DK2830662T3 (da) * | 2012-03-29 | 2019-01-02 | Univ Columbia | Fremgangsmåder til behandlng af hårtabsforstyrrelser |
| MX368511B (es) | 2012-06-22 | 2019-10-07 | Galapagos Nv | Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma. |
| EP3060234A1 (en) * | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| SMT202300328T1 (it) | 2015-04-13 | 2023-11-13 | Galapagos Nv | Metodi per il trattamento di disturbi cardiovascolari |
| KR20170134750A (ko) | 2015-04-13 | 2017-12-06 | 갈라파고스 엔.브이. | 염증 질환의 치료 방법 |
| AU2016259023A1 (en) * | 2015-05-07 | 2017-11-30 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for promoting hair growth |
-
2017
- 2017-11-09 JP JP2019524273A patent/JP2019534304A/ja not_active Withdrawn
- 2017-11-09 AU AU2017358703A patent/AU2017358703A1/en not_active Abandoned
- 2017-11-09 EP EP17800795.1A patent/EP3538103A1/en not_active Withdrawn
- 2017-11-09 RU RU2019117562A patent/RU2019117562A/ru not_active Application Discontinuation
- 2017-11-09 WO PCT/EP2017/078701 patent/WO2018087202A1/en not_active Ceased
- 2017-11-09 CA CA3043396A patent/CA3043396A1/en not_active Abandoned
- 2017-11-09 US US16/348,799 patent/US20190314382A1/en not_active Abandoned
- 2017-11-10 TW TW106139074A patent/TW201821080A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3538103A1 (en) | 2019-09-18 |
| TW201821080A (zh) | 2018-06-16 |
| JP2019534304A (ja) | 2019-11-28 |
| WO2018087202A1 (en) | 2018-05-17 |
| AU2017358703A1 (en) | 2019-05-09 |
| US20190314382A1 (en) | 2019-10-17 |
| RU2019117562A3 (cg-RX-API-DMAC7.html) | 2021-02-09 |
| CA3043396A1 (en) | 2018-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534304A5 (cg-RX-API-DMAC7.html) | ||
| JP2020526483A5 (cg-RX-API-DMAC7.html) | ||
| JP2023528804A5 (cg-RX-API-DMAC7.html) | ||
| Daniels et al. | Is the Parkland formula still the best method for determining the fluid resuscitation volume in adults for the first 24 hours after injury?—A retrospective analysis of burn patients in Germany | |
| Memme et al. | Activating transcription factor 4 regulates mitochondrial content, morphology, and function in differentiating skeletal muscle myotubes | |
| Polyák et al. | Long-term endurance training-induced cardiac adaptation in new rabbit and dog animal models of the human athlete’s heart | |
| AU2016276488A1 (en) | Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis | |
| WO2014134569A1 (en) | Compositions and methods for treating amyotrophic lateral sclerosis in responders | |
| KR20160079899A (ko) | 신경퇴행성 질환 또는 인지 결핍을 치료하기 위한 인돌릴 및 이돌리닐 하이드록사메이트의 용도 | |
| ES2575676T3 (es) | Composición de colirio | |
| Shimojima et al. | Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation | |
| Cavalcanti et al. | Low‐intensity treadmill exercise‐related changes in the rat stellate ganglion neurons | |
| RU2013156363A (ru) | Диагностика инфекционного заболевания дыхательных путей с использованием образцов крови | |
| CN115175682A (zh) | 使用布鲁顿氏酪氨酸激酶的抑制剂治疗原发进展型多发性硬化症的方法 | |
| WO2025098219A1 (zh) | 川芎嗪硝酮衍生物在制备预防或治疗肌少症药物中的应用 | |
| Tourette et al. | Biophytis BIO101 in sarcopenia: Update on the SARA program: From SARA-INT towards the phase 3 study | |
| Alla et al. | Clinical profiles of elderly patients presenting with persistent dizziness | |
| Gandar et al. | In vitro and in vivo assessment of eprociclovir as antiviral treatment against testudinid herpesvirus 3 in Hermann's tortoise (Testudo hermanni) | |
| US10806739B2 (en) | Use of n-desmethylclobazam in the treatment of chronic pain disorders and related methods | |
| Suzuki et al. | Dose-dependent increase in the QTc interval in aripiprazole treatment after risperidone. | |
| Villanueva et al. | Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits | |
| Seada et al. | Implication changes of serum adiponectin in chronic Moderate aerobic and resistant pattern of exercise in male albino rat model of Alzheimer | |
| Derakhchan et al. | Evaluation of cardiac conduction disturbances using jacketed external telemetry (JET) in conscious non-human primates (NHP) | |
| Acosta Viana et al. | Effectiveness of Intralesional Triamcinolone in the Treatment of Keloids in Children | |
| HK40082153A (en) | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210804 |